355 patents currently held
19 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Feb 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
47
Ending by 2030
Feb 2027
Next term end
275
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2035 · Medium confidence
Also notable
Ends Aug 2038 · High confidence
Also notable
Ends Jan 2030 · High confidence
Also notable
Ends May 2030 · High confidence
Also notable
Ends Nov 2037 · High confidence
Also notable
Ends May 2033 · High confidence
Also notable
Ends Jun 2029 · High confidence
Also notable
Ends May 2035 · High confidence
Compositions and Methods for Treatment and Detection of Cancers
US 10,150,818
The most cited patent in this portfolio, cited by 55 later US patents, top 5% of utility patents granted in 2018 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
Microscope-Based System and Method for Image-Guided Microscopic Illumination
US 11,265,449
Cited by 5 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2038.
Globo H and Related Anti-Cancer Vaccines with Novel Glycolipid Adjuvants
US 8,268,969
Cited by 48 later US patents, top 25% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Two-Fluid Molten-Salt Reactor
US 8,594,268
Cited by 26 later US patents, top 25% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Recombinant Virus, Composition Comprising the Same, and Uses Thereof
US 11,480,391
Cited by 7 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2037.
Capture, Purification, and Release of Biological Substances Using a Surface Coating
US 9,541,480
Cited by 18 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Alkynyl Sugar Analogs for the Labeling and Visualization of Glycoconjugates in Cells
US 7,960,139
Cited by 32 later US patents, top 25% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Batch-Process Supertorrefaction System and Method
US 10,273,411
Granted 2019 and renewed at 2 of 3 maintenance windows. Protection runs to 2035.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Compounds for Use in Prevention and Treatment of Neurodegenerative Diseases and Pain (US 10,301,348) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 12 fees due Dec 4 to 30, 2026 · next Dec 4
- 7 fees due Jan 2 to 9, 2027 · next Jan 2
- 9 fees due Feb 1 to 28, 2027 · next Feb 1
- 6 fees due Mar 3 to 17, 2027 · next Mar 3
- 5 fees due Apr 3 to 17, 2027 · next Apr 3
- 8 fees due May 3 to 28, 2027 · next May 3
- 5 fees due Jun 3 to 10, 2027 · next Jun 3
- 13 fees due Jul 2 to 30, 2027 · next Jul 2
- 3 fees due Aug 11 to 25, 2027 · next Aug 11
- 12 fees due Sep 3 to 30, 2027 · next Sep 3
- 5 fees due Oct 7 to 30, 2027 · next Oct 7
- 2 fees due Nov 14 to 17, 2027 · next Nov 14
Recent changes
- 7 of the patents on this record were granted since Aug 22, 2026
- 10 terms have ended since Aug 22, 2026
- Nov 16 US 7,453,565 Substrate for Surface-Enhanced Raman Spectroscopy, Sers Sensors, and Method for Preparing Same · term ended
- Oct 30 US 10,112,198 Collector Architecture Layout Design · lapsed on the fee record
- Oct 24 US 7,943,134 Compositions and Methods for Identifying Response Targets and Treating Flavivirus Infection Responses · term ended
- Oct 14 US 8,858,776 Preparation of Graphene Sheets · lapsed on the fee record
- Oct 2 US 10,087,450 Engineered Yeast for Production of Enzymes · lapsed on the fee record
- Sep 30 US 8,846,623 Cancer-Targeting Peptides and Uses Thereof in Cancer Treatment and Diagnosis · lapsed on the fee record
- Sep 27 US 8,594,999 Typing Candidate Generating Method for Enhancing Typing Efficiency · term ended
- Sep 11 US 10,072,097 Compositions and Methods for Detection of Protein S-Nitrosylation and Oxidation · lapsed on the fee record
- Sep 9 US 8,829,172 Novel Multiplex Barcoded Paired-End Ditag (mbPED) Sequencing Approach and Its Application in Fusion Gene Identification · lapsed on the fee record
- Sep 7 US 7,569,545 Methods of Increasing Neurotrophic Factor Expression · term ended
What they patent
The largest of its 275 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,618,938 | Treating Cerebrovascular Diseases with Erythropoietin and Granulocyte-Colony Stimulating Factor Jointly In force · High confidence | In force | High confidence | |
| US 8,597,701 | Transcription modulator compositions In force · High confidence | In force | High confidence | |
| US 7,763,285 | Polyacetylenic Compounds In force · High confidence | In force | High confidence | |
| US 8,142,999 | Hla Alleles Associated with Adverse Drug Reactions and Methods for Detecting Such held by Academia Sinica and Pharmigene Inc. In force · High confidence | In force | High confidence | |
| US 7,649,170 | Dual-Polarity Mass Spectrometer In force · High confidence | In force | High confidence | |
| US 7,547,455 | Cancer and Inflammatory Disorder Treatment In force · High confidence | In force | High confidence | |
| US 8,129,357 | Method of Making and Using an Adenosine Analogue In force · High confidence | In force | High confidence | |
| US 10,317,393 | Alkynyl Sugar Analogs for Labeling and Visualization of Glycoconjugates in Cells In force · High confidence | In force | High confidence | |
| US 8,048,455 | Treatment of Cancer and Inflammatory Disorder In force · High confidence | In force | High confidence | |
| US 7,923,007 | Brain Tissue Damage Therapies In force · High confidence | In force | High confidence |
Also on record, not counted in the 355: 19 patents in force now held by others · 290 patents ended · 107 applications pending · 233 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.